Diaziquone

Drug Profile

Diaziquone

Alternative Names: AZQ; CI 904; NSC 182986

Latest Information Update: 30 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); Nonindustrial source
  • Developer National Institutes of Health (USA)
  • Class Aziridines; Benzoquinones; Cytostatics; Small molecules
  • Mechanism of Action Alkylating agents; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported CNS cancer

Most Recent Events

  • 08 Jul 1999 Discontinued-III for CNS cancer in USA (IV)
  • 02 Jun 1995 A study has been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top